Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPTUNUS extension study of ianalumab in active Sjögren's syndrome
MOH_2024-01-08_013170Phase 3Not yet recruiting
- Sponsor
- Novartis
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ianalumab in Sjögren's syndrome (4 arms), sponsored by Novartis. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
ianalumab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on MOH_2024-01-08_013170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-08_013170.